We have retrospectively investigated the relationship between the level of minimal residual disease (MRD) detected in bone marrow taken prior to conditioning therapy and outcome following stem cell transplantation for high risk childhood ALL. Forty-one patients, in whom both a molecular marker of MRD and sufficient archival material was available, were included in the study. All were in remission at BMT: eight in CR1, 32 in CR2 and five in greater than CR2. MRD was measured by PCR amplification of antigen receptor gene rearrangements and clone-specific oligoprobing, the median sensitivity of detection being one leukaemic cell in 10 000 normals. Results were classified as high-level positive (if a clonal band was evident after electrophoresis), low-level positive (if MRD was detected only after oligoprobing) and negative. MRD was detected at high levels in 17 patients, at low levels in 10 patients and 14 patients were MRD negative at the time of transplant. The 5-year event-free survival for these groups was 23%, 48% and 78%, respectively (P = 0.022). Limited multivariate analysis confirmed the significance of MRD (P = 0.0095) vs CR status, donor type, sex, immunophenotype and acute GvHD. This study confirms the strong relationship between MRD level and outcome following allogeneic transplantation. In contrast to a previous study we observed that a minority of children with high-level pre-BMT MRD can enter long lasting remission. The possible role for acute GVHD coupled with a graft-versus-leukaemia effect in the clearance of high level MRD in patients with ALL is discussed.
Introduction
Several studies have now described a strong correlation between minimal residual disease burden immediately prior to conditioning for allogeneic BMT for ALL and outcome. [1] [2] [3] [4] It is likely that the clinical significance of MRD varies according to previous therapy, transplant protocol and the method used for detection of residual disease. In order to confirm this hypothesis we used the method employed in a previous study of a cohort of children transplanted in Bristol, UK 2 to investigate the prognostic value of MRD in 45 patients undergoing allo-SCT in remission for relapsed or high-risk ALL in Tüb-ingen, Germany.
Patients, materials and methods

Patients
Between March 1986 and October 1999 59 children and adolescents aged less than 18 years were transplanted for relapsed or high risk ALL at the University Children's Hospital of Tü bingen, Germany. Twelve were excluded due to lack of suitably archived material and two were not in haematological remission at the time of transplantation. Thus 45 patients (24 males) aged between 1.5 and 17.8 years (median 9.8 years) at diagnosis were studied. In four cases a clone-specific marker of MRD was not detected in leukaemic DNA, leaving 41 open for further investigation. Diagnosis of ALL was confirmed by morphological and immunophenotypic analysis using standard criteria. 5 Eighteen patients had common ALL, nine pre-B ALL, 12 pre-T/T-ALL and in two patients no immunophenotypic data were available. Seven patients transplanted in CR1 for high risk disease (t(9;22) n = 5, T cell phenotype and prednisone poor response n = 2) received intensive chemotherapy according to the BFM protocols 86 (n = 1), 90 (n = 4) and 95 (n = 2). Those transplanted in CR2 or in higher CR (29 in CR2, three in CR3 and two in CR4) received intensive chemotherapy prior to allo-SCT according to the BFM ALL REZ protocols 85 (n = 2), 89 (n = 4), 90 (n = 12), 94 (n = 3), 95 (n = 1) and 96 (n = 12). Nineteen patients were transplanted with grafts from HLA-identical siblings, 18 from HLA-identical unrelated donors and four from mismatched family donors. Informed consent was obtained in accordance with institutional regulations. HLA-typing for class I (A and B) was carried out serologically; for class II alleles (DRB1) molecular methods were used routinely for patients grafted after 1995. Details of patient characteristics are given in Table 1 .
Transplant procedures
A variety of conditioning regimens was employed. Children transplanted from HLA-identical siblings received fractionated TBI (12 Gy) and etoposide (60 mg/kg) (n = 18) or TBI (12 Gy), cyclophosphamide (2 × 60 mg/kg) and etoposide (60 mg/kg) (n = 1). Patients grafted from matched unrelated donors (n = 13) received either TBI (12 Gy), cyclophosphamide (2 × 60 mg/kg) and anti-lymphocyte globulin (60 mg/kg) (n = 13) or TBI (12 Gy), cyclophosphamide (2 × 60 mg/kg), thiotepa (10 mg/kg) and OKT 3 (n = 5). Those with an HLA-mismatched family donor received TBI (12 Gy), cyclophosphamide (2 × 60 mg/kg), thiotepa (10 mg/kg) and anti-lymphocyte globulin (60 mg/kg) (n = 2) or children aged less than 3 years of age (n = 2) received busulfan (16 mg/kg), cyclophosphamide (2 × 60 mg/kg), thiotepa (10 mg/kg) and anti-lymphocyte globulin (60 mg/kg). Twenty-eight patients receiving unmanipulated grafts were given cyclosporine A (CsA) either alone or in combination with methotrexate as GVHD prophylaxis. No posttransplant GVHD prophylaxis was given to 13 children transplanted with CD34-positive enriched stem cells. 6 Details of GVHD are given in Table 1 . Clinical grading of GVHD was performed according to Refs 7 and 8. ); TT, thiotepa.
Samples
MRD was analysed in bone marrow samples taken for remission control prior to conditioning. DNA was extracted from EDTA anticoagulated bone marrow aspirates using QIAamp kits (Qiagen, Hilden, Germany) according to the manufacturer's instructions. In 20 cases where no BM aspirate was available DNA was obtained from archival BM slides as described previously.
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Characterization of clone-specific rearrangements and investigation of remission specimens
Leukaemic material from diagnosis or last relapse pre-BMT was screened for IGH, TCRD, or TCRG rearrangements using PCR amplification with FR3-JH, V␦2-D␦3 and V␥1/9-J␥1.1/2.1 and J␥1.3/2.3 primer pairs. Clonal bands were sequenced directly and 20 base oligonucleotides were syntheLeukemia sized to map to the DNJ (IGH), VND (V␦2-D␦3) or VNJ (V␥1/9-J␥1.1/2.1-1.3/2.3) junctions. Amplifiability of each pre-BMT sample was assessed by VNTR/STR-PCR as reported previously. 10 PCR products were separated by 8% PAGE and transferred to a nylon membrane by semi-dry electroblotting. The membranes were probed using the leukaemia-specific oligonucleotide end-labelled with ␥ 32 P-dATP, followed by autoradiography. High-level MRD (believed to represent disease at a level of at least one leukaemic cell in 1000 normals) was defined as that evident as a clonal band after PAGE. Low-level MRD (believed to represent disease at a level between at least one leukaemic cell in 100 000 normal cells and one in 1000 normal cells) was defined as that identified only after oligoprobing.
Statistics
The 2 -test was used to compare relapse rates between the three MRD groups. Actuarial probabilities of EFS were calcu-Leukemia lated using the method of Kaplan and Meier where an event was defined as relapse or death. Univariate and multivariate analysis was performed using the Cox proportional hazards model to assess the independence of MRD as risk factor for relapse. The results have been analyzed up to November 2000, which allows a minimum follow-up of 12 months for patients in continuing complete remission (CCR).
Results
Rearrangements
Sixty-five clonal rearrangements (28 IGH, 16 V␦2, 14 V␥1, 7 V␥9) were identified for 45 patients. One rearrangement was found in 27 patients, two in 11, three in four and four in one. In four patients no rearrangement could be identified. Sequence-specific probes were synthesized for all available IGH-DNJ sequences and each unique TCRD or TCRG rearrangement. Patients were studied with all available patient-specific probes. Discrepant results were found in six patients: one in whom four different rearrangements could be identified at presentation, was gel positive for three rearrangements but only probe positive for the fourth. In another patient, who showed two rearrangements at presentation, only one was found to be detectable on PAGE prior to transplant whereas the other could be identified after probing. Four other children were negative with one probe but low-level positive with another. The first two cases were rated as having highlevel positive MRD and the latter four low-level positive MRD for the purposes of our analysis.
Patterns of MRD
Three patients died due to transplant-related complications after 180, 277 and 280 days, respectively. As they survived free of relapse for more than 100 days they were included in the analysis of the impact of MRD. Results for each patient subgroup are given in Table 1 . Follow-up of the surviving patients ranged from 1 to 11.8 years (median 5.75 years). Of 14 children who were MRD negative prior to SCT 11 survive, two died of relapse and one died due to infection. Of 10 with low-level MRD, five relapsed and five survived. Seventeen patients had high-level MRD. Of these, 11 relapsed and two died due to extensive graft-versus-host disease. Four remain in CCR. Each of these was transplanted with an unmanipulated graft from either an HLA-identical sibling (n = 3) or from an HLA-identical unrelated donor (n = 1). Two developed severe aGVHD grade III that was finally controlled by immunosuppressive agents. One patient developed only mild aGVHD grade I. The fourth, a patient with Philadelphia chromosomepositive B-ALL, received additional immune modulation post SCT. This child developed increasing recipient cells up to 40% on day 112 post transplant. On the same day bcr/abl translocation was re-detected in the bone marrow. Therefore CsA was withdrawn and the patient developed severe aGVHD grade III. The autologous cells and the bcr/abl transcript disappeared and the patient remains in CCR with a follow-up of more than 4 years. 11 The probability of event-free survival at 5 years in all patients in whom high-level MRD was identified was 0.23 (s.e. ± 0.10), for low-level positive patients 0.48 (s.e. ± 0.16) and MRD-negative patients 0.78 (s.e. ± 0.11). These differences are statistically significant (P = 0.022). The Kaplan-
Figure 1
Kaplan-Meier analysis of all patients with regard to their MRD level prior to SCT. Kaplan-Meier plots comparing event-free survival of MRD negative (n = 14), low-level MRD-positive (n = 10) and high-level MRD-positive patients (n = 17). The 5 year EFS is given for each MRD category at the end of each curve.
Meier plots are given in Figure 1 . The incidence of relapse was also significantly different when comparing patients showing either any level of MRD pre-transplant to those in whom MRD could not be detected prior to transplantation (P = 0.011). The probabilities at 5 years event-free survival is given in Figure  2 . The 2 year event-free survival for patients with high-level MRD who received an unmanipulated allograft was 28% (± 0.12) and for patients who received a T cell-depleted allograft 0%.
Cox proportional hazards analysis in all patients showed that only MRD was significantly related to EFS (P = 0.0071) but sex, immunophenotype, donor, GVHD and remission status did not influence post-transplant outcome. Multivariate
Figure 2
Kaplan-Meier analysis of MRD-negative and -positive patients. Kaplan-Meier plots comparing event-free survival of MRD negative (n = 14) and MRD positive (low and high) (n = 27). The 5 year EFS is given for each MRD category at the end of each curve.
analysis confirmed the significance of MRD (P = 0.0095) after separate adjustment for pre-SCT CR status, type of donor (related vs unrelated), sex, immunophenotype and aGVHD in all patients.
Separate statistical analysis was performed in patients transplanted in CR2 (n = 32 (29 elsewhere)). In univariate analysis significant results were obtained for the level of MRD (P = 0.0080) and when comparing patients with very early (Ͻ18 months) or late relapses (Ͼ30 months) (P = 0.0185). Pre-BMT MRD level was the only significant parameter (P = 0.0080) in multivariate analysis incorporating duration of CR1, immunophenotype, graft manipulation, donor type, aGVHD, sex and MRD level.
Discussion
Bone marrow transplantation is currently the most intensive, expensive and dangerous therapy available for childhood ALL. 12 Consequently, it is vital that it is used both sparingly and effectively. Several papers have recently reported a strong correlation between pre-BMT MRD load and risk of posttransplant relapse. 2, 3 In the largest of these studies, Knechtli et al 2 reported that all 12 children with high level MRD prior to BMT relapsed. This led to the suggestion that BMT may be futile for such children. 13 In the current study, 17 patients were categorized as having high-level MRD prior to transplantation. Four have survived. The small numbers of patients and differences in conditioning regimens within each study mean that it is not possible to draw firm conclusions as to the factors responsible for this difference. However, three pieces of evidence support speculation that graft-versus-leukaemia (GVL) may play a role. Firstly, all four survivors of high-level MRD developed GVHD. In a recent publication from Stockholm, 3 development of GVHD was the prime determinant of outcome in patients with MRD prior to BMT for ALL. Secondly, the majority of children transplanted in Bristol 2 received grafts which had been T cell depleted with CAMPATH both in vivo and in vitro, whereas all survivors of high-level MRD in this study received unmanipulated grafts. Thirdly, two of four survivors had Ph + -positive ALL, a leukaemia commonly held to be a 'good' target for GVL, and in one of these cases relapse appears to have been prevented by immune modulation.
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Five of 10 patients with MRD detectable at lower levels before SCT remain in remission, suggesting that conditioning therapy or a GVL effect successfully eliminated their residual disease. It is possible that further subdivision of risk for this group may be achieved by the use of truly quantitative real time PCR. 14, 15 In the present study only 2/14 patients in whom MRD was undetectable pre-BMT went on to relapse. False negative results due to clonal evolution 16, 17 were not excluded in either patient due to the absence of DNA from the time of relapse post transplant.
We conclude that allogeneic stem cell transplantation may benefit a minority of children with ALL and a high burden of MRD prior to transplant, particularly if the transplant protocol favours development of significant GVHD. An alternative approach may be to give further cytoreductive chemotherapy prior to BMT, attempting to render the patient MRD negative. The optimal approach can only be defined by large prospective studies which incorporate measurement of MRD using standardized quantitative techniques. The development of such technology is now the focus of an international collaboration with participating centres from the Czech Republic, Denmark, Germany, The Netherlands and the UK.
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